Celgene Trial Disappointment No Disaster

In this video, Motley Fool health-care analyst David Williamson discusses some phase 3 trial results for Celgene's pipeline drug Apremilast in the treatment of psoriasis. Investor excitement over the drug had been raised to a fever pitch, so when the drug failed to hit the same high marks it had reached in phase 2, there was some disappointment. However, in the video, David tells investors everything that the drug still has going for it, and why it may have a leg up on the competition in this space.

Can Celgene continue to soar?
Every in-the-know biotech investor has an eye on Celgene. Shares have skyrocketed this year as the company outlined a plan to almost triple its profits in only a few years. But should you buy the story Celgene is selling? Make sure you understand the key opportunities and risks facing this company by picking up The Motley Fool's brand-new premium report on Celgene. To claim your copy today -- along with a free year of updates -- simply click here now.

The article Celgene Trial Disappointment No Disaster originally appeared on Fool.com.

David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story